Breaking News Instant updates and real-time market news.

AKRX

Akorn

$4.03

-0.42 (-9.44%)

, FSNUY

Fresenius SE

$0.00

(0.00%)

17:28
02/20/19
02/20
17:28
02/20/19
17:28

Akorn 'strongly contests' Fresenius' proposed amended claims

Akorn, Inc. (AKRX) said that it "strongly contests Fresenius' (FSNUY) proposed amended claims filed earlier today. Akorn believes these claims are meritless and overreaching. Akorn denies the allegations and will vigorously defend itself in this litigation, while continuing to focus on advancing its pipeline, strengthening its business and developing a strategic plan for improving financial performance and long-term shareholder value."

AKRX

Akorn

$4.03

-0.42 (-9.44%)

FSNUY

Fresenius SE

$0.00

(0.00%)

  • 01

    May

AKRX Akorn
$4.03

-0.42 (-9.44%)

11/26/18
RBCM
11/26/18
NO CHANGE
RBCM
Sector Perform
Akorn gets FDA approval for generic Voltaren Gel, says RBC Capital
RBC Capital analyst Randall Stanicky said his "back and forth with management" at Akorn confirmed that the company received FDA approval for its generic version of Voltaren Gel, which the analyst notes represents the third ANDA approval from the company's Amityville facility since October. Stanicky, who continues to watch the company's ongoing litigation as well as its progress on the remediation of its Decatur and Somerset facilities, keeps a Sector Perform rating on Akorn shares.
11/27/18
PIPR
11/27/18
NO CHANGE
Target $9
PIPR
Overweight
Akorn approval an 'encouraging development,' says Piper Jaffray
Piper Jaffray analyst David Amsellem views Akorn's (AKRX) approval of its generic of Voltaren Gel as an "encouraging development." The news demonstrates that the company can execute on the approval of products on the more technically challenging end of the generics spectrum, Amsellem tells investors in a research note. The analyst believes Akorn is well positioned for "significant EBITDA recovery" over the next two years. He sees a "high likelihood" that the company in 2018 will have worked through the bulk of the erosion of key generics due to competition and a "relatively high" probability of meaningful cost reductions if it loses its appeal in its case against Fresenius (FSNUY). Amsellem reiterates an Overweight rating on Akorn with a $9 price target.
12/07/18
CHLM
12/07/18
NO CHANGE
Target $11
CHLM
Buy
Craig-Hallum maintains Buy rating, $11 target on Akorn after Fresenius ruling
Craig-Hallum analyst Matt Hewitt said the Delaware Supreme Court ruling in favor of Fresenius (FSNUY) ends any hopes that a merger with Akorn (AKRX) will still occur, which may be a disappointment to some investors. However, it has been his view since the first ruling was announced that Akorn should be valued on a standalone basis. Akorn currently has a large pipeline of higher margin generics and the company's low-cost manufacturing facility in India has been idled due to the terms of the Fresenius agreement, but is likely to be brought online sometime in FY19 or FY20, Hewitt tells investors. He keeps a Buy rating and $11 price target on Akorn shares, which are down $1.34, or 24%, to $4.25 in afternoon trading.
12/10/18
PIPR
12/10/18
NO CHANGE
Target $9
PIPR
Overweight
Piper does not view Akorn as 'major fixer-upper,' keeps $9 target
Piper Jaffray analyst David Amsellem says he would not view Akorn (AKRX) as a "major fixer-upper" now that it is planning to move forward as a stand-alone company. Much of the pressure on EBITDA in recent years was a function of limited-competition products with brand-like margins, Amsellem tells investors in a research note. Further, the rest of Akorn's product portfolio appears to be stable, says the analyst. In addition, "high-quality" abbreviated new drug application approvals have been happening, "and that matters," argues Amsellem. He keeps an Overweight rating on Akorn with a $9 price target.
FSNUY Fresenius SE
$0.00

(0.00%)

12/18/18
GSCO
12/18/18
UPGRADE
GSCO
Buy
Fresenius SE upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded Fresenius SE to Buy, stating that its fundamentals remain compelling after the recent sell-off has reset expectations.
12/19/18
GSCO
12/19/18
UPGRADE
GSCO
Buy
Goldman upgrades Fresenius SE to Buy after 33% pullback
Goldman Sachs analyst Veronika Dubajova last night upgraded Fresenius SE to Buy from Neutral while lowering her price target for the shares to EUR 52 from EUR 61. The stock's 33% decline in three months has brought a "compelling entry point into a largely defensive business," Dubajova tells investors in a research note. The analyst believes Fresenius is "exposed to a number of attractive verticals with mid-to-high-single digit revenue and earnings growth potential." She looks to the company's fiscal 2018 results on February 20 as the next catalyst for the shares.
01/15/19
LEHM
01/15/19
DOWNGRADE
LEHM
Equal Weight
Fresenius SE downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Hassan Al-Wakeel downgraded Fresenius SE to Equal Weight and lowered his price target for the shares to EUR 51 from EUR 70. Changes to German hospital pricing regulations in 2020 could negatively impact the company's margins, Al-Wakeel tells investors in a research note.

TODAY'S FREE FLY STORIES

SCVL

Shoe Carnival

$33.03

0.18 (0.55%)

17:08
09/19/19
09/19
17:08
09/19/19
17:08
Hot Stocks
Shoe Carnival appoints CEO Cliff Sifford as vice chairman »

Shoe Carnival announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FQVLF

First Quantum Minerals

$0.00

(0.00%)

17:06
09/19/19
09/19
17:06
09/19/19
17:06
Periodicals
First Quantum Minerals seeing takeover interest, Bloomberg reports »

First Quantum Minerals,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GVP

GSE Systems

$1.75

0.06 (3.55%)

17:05
09/19/19
09/19
17:05
09/19/19
17:05
Syndicate
GSE Systems requests withdrawal of registration statement »

The company is requesting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JWN

Nordstrom

$32.15

-0.46 (-1.41%)

17:01
09/19/19
09/19
17:01
09/19/19
17:01
Hot Stocks
Nordstrom names Kenneth Worzel as new COO »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$6.04

-0.13 (-2.11%)

, RGR

Sturm, Ruger

$42.84

-0.28 (-0.65%)

16:59
09/19/19
09/19
16:59
09/19/19
16:59
Hot Stocks
Gun maker Colt to stop making AR-15s and other long guns for the civilian market »

Gunmaker Colt says it is…

AOBC

American Outdoor Brands

$6.04

-0.13 (-2.11%)

RGR

Sturm, Ruger

$42.84

-0.28 (-0.65%)

VSTO

Vista Outdoor

$6.47

-0.105 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

ARNC

Arconic

$27.14

-0.17 (-0.62%)

16:55
09/19/19
09/19
16:55
09/19/19
16:55
Hot Stocks
Arconic to sell forgings business in U.K. to Aero Forgings for roughly $62M »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

DOVA

Dova Pharmaceuticals

$16.00

0.5 (3.23%)

, RIGL

Rigel Pharmaceuticals

$1.71

0.015 (0.89%)

16:55
09/19/19
09/19
16:55
09/19/19
16:55
Conference/Events
Wedbush biotech analysts to hold a dinner meeting »

Biotech Analysts…

DOVA

Dova Pharmaceuticals

$16.00

0.5 (3.23%)

RIGL

Rigel Pharmaceuticals

$1.71

0.015 (0.89%)

ARGX

Argenx

$126.44

-0.94 (-0.74%)

MNTA

Momenta

$13.35

-0.14 (-1.04%)

AMGN

Amgen

$195.64

0.67 (0.34%)

NVS

Novartis

$86.39

0.09 (0.10%)

ALNY

Alnylam

$84.68

-0.87 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 24

    Oct

  • 04

    Feb

BYND

Beyond Meat

$155.04

1.31 (0.85%)

, TSLA

Tesla

$246.51

3.08 (1.27%)

16:48
09/19/19
09/19
16:48
09/19/19
16:48
Hot Stocks
Beyond Meat names Sanjay Shah COO »

Beyond Meat (BYND)…

BYND

Beyond Meat

$155.04

1.31 (0.85%)

TSLA

Tesla

$246.51

3.08 (1.27%)

AMZN

Amazon.com

$1,822.21

4.21 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Oct

  • 12

    Nov

SMTX

SMTC Corp.

$2.96

0.16 (5.71%)

16:40
09/19/19
09/19
16:40
09/19/19
16:40
Earnings
SMTC Corp. guides initial FY20 revenue $390M-$410M, two estimate $421.85M »

Guides initial FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CLXT

Calyxt

$6.97

-0.2 (-2.79%)

16:40
09/19/19
09/19
16:40
09/19/19
16:40
Hot Stocks
Calyxt signs seed agreement with Landus Cooperative in Iowa »

Calyxt has added Landus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMTX

SMTC Corp.

$2.96

0.16 (5.71%)

16:39
09/19/19
09/19
16:39
09/19/19
16:39
Earnings
SMTC Corp to exit China operations, cuts FY19 revenue view to $354M-$362M »

Two estimates $392.79M. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ACRGF

Acreage Holdings

$0.00

(0.00%)

16:36
09/19/19
09/19
16:36
09/19/19
16:36
Initiation
Acreage Holdings initiated  »

Acreage Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMTX

SMTC Corp.

$2.96

0.16 (5.71%)

16:36
09/19/19
09/19
16:36
09/19/19
16:36
Hot Stocks
Breaking Hot Stocks news story on SMTC Corp. »

SMTC Corp to exit China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

16:35
09/19/19
09/19
16:35
09/19/19
16:35
General news
Money Supply M2 Weekly Change data reported »

Week of 9/9 Money Supply…

16:35
09/19/19
09/19
16:35
09/19/19
16:35
General news
Fed Balance Sheet Level data reported »

Week of 9/18 Fed Balance…

FSLR

First Solar

$67.09

1.32 (2.01%)

16:35
09/19/19
09/19
16:35
09/19/19
16:35
Hot Stocks
First Solar transitions to leveraging third-party EPC services »

First Solar, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

HEXO Corp

$3.94

-0.175 (-4.25%)

16:35
09/19/19
09/19
16:35
09/19/19
16:35
Initiation
HEXO Corp initiated  »

HEXO Corp initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CURLF

Curaleaf Holdings

$0.00

(0.00%)

16:34
09/19/19
09/19
16:34
09/19/19
16:34
Initiation
Curaleaf Holdings initiated  »

Curaleaf Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CHNR

China Natural Resources

$2.53

0.13 (5.42%)

16:34
09/19/19
09/19
16:34
09/19/19
16:34
Syndicate
Breaking Syndicate news story on China Natural Resources »

China Natural Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$18.04

-0.18 (-0.99%)

16:32
09/19/19
09/19
16:32
09/19/19
16:32
Hot Stocks
KeyCorp CEO Beth Mooney to retire »

KeyCorp announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ASA

ASA Limited

$12.56

0.25 (2.03%)

16:31
09/19/19
09/19
16:31
09/19/19
16:31
Hot Stocks
ASA Limited reports NAV positive 59.4% for 9 months ended August 31 »

ASA Gold and Precious…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/19/19
09/19
16:30
09/19/19
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

NDLS

Noodles & Company

$5.92

-0.05 (-0.84%)

16:29
09/19/19
09/19
16:29
09/19/19
16:29
Hot Stocks
Noodles & Company names Jeffrey Jones as board chairman »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRY

Tilray

$29.91

-0.59 (-1.93%)

16:29
09/19/19
09/19
16:29
09/19/19
16:29
Initiation
Tilray initiated  »

Tilray initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

MSFT

Microsoft

$141.08

2.55 (1.84%)

, TGT

Target

$107.84

0.92 (0.86%)

16:29
09/19/19
09/19
16:29
09/19/19
16:29
On The Fly
Fly Intel: Wall Street's top stories for Thursday »

Stocks spent the morning…

MSFT

Microsoft

$141.08

2.55 (1.84%)

TGT

Target

$107.84

0.92 (0.86%)

MO

Altria Group

$40.12

-0.72 (-1.76%)

PM

Philip Morris

$71.70

0.12 (0.17%)

GE

General Electric

$9.41

0.03 (0.32%)

CBPO

China Biologic

$113.97

10.78 (10.45%)

MLHR

Herman Miller

$45.05

0.57 (1.28%)

X

U.S. Steel

$11.06

-1.39 (-11.16%)

GRUB

GrubHub

$60.54

-3.245 (-5.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 25

    Sep

  • 21

    Oct

  • 22

    Oct

  • 27

    Oct

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.